Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Does BPC 157 Make You Stronger? The Real Science Explained

It’s one of the most common questions our team gets from researchers in the athletic and performance communities. The query is usually straightforward, packed with hope and curiosity: does BPC 157 make you stronger? It’s a simple question with a surprisingly c

It’s one of the most common questions our team gets from researchers in the athletic and performance communities. The query is usually straightforward, packed with hope and curiosity: does BPC 157 make you stronger? It’s a simple question with a surprisingly complex and nuanced answer. Let's be honest, if you're looking for a compound that directly adds plates to your barbell overnight, you might be looking in the wrong place. But if you're interested in the foundational mechanics of what builds and sustains elite-level strength, then you’ve absolutely landed in the right spot.

Here at Real Peptides, we're not just suppliers; we're deeply immersed in the science of these incredible molecules. Our work involves meticulous small-batch synthesis to ensure every peptide, including our research-grade BPC 157 Peptide, meets the highest purity standards. This precision gives us a unique perspective on how these compounds function. The answer to the strength question isn't a simple yes or no. It's about understanding that real, lasting strength isn't just about raw force production. It’s about resilience. It’s about recovery. And it's about the integrity of the entire musculoskeletal system. That is where BPC 157 truly enters the conversation, and it’s a game-changer.

First, Let’s Clear the Air: What BPC 157 Is (and Isn't)

Before we dive deep, we need to establish a baseline. What exactly is Body Protection Compound 157? BPC 157 is a pentadecapeptide, meaning it's a sequence of 15 amino acids. It's a synthetic peptide, but it’s derived from a protective protein found naturally in the stomach. Its initial discovery was tied to its cytoprotective qualities—its ability to protect cells from harm. That's its origin story.

Over time, research has revealed a sprawling list of potential systemic effects, most of which center around healing and regeneration. It's often called a 'stable gastric pentadecapeptide' primarily because of its extraordinary stability in human gastric juice, unlike many other peptides. This stability is a critical feature.

But here's what it isn't: BPC 157 is not an anabolic steroid. It's not a SARM (Selective Androgen Receptor Modulator). It doesn't function by directly binding to androgen receptors to force muscle protein synthesis in the way testosterone or its derivatives do. This is a crucial distinction. We can't stress this enough. Anyone conflating BPC 157 with traditional anabolic agents is fundamentally misunderstanding its mechanism of action. Thinking of it in those terms will only lead to confusion and misplaced expectations.

It’s a regenerative compound. A healing facilitator. A systems optimizer. Not a blunt instrument for hypertrophy. Understanding this is the key to unlocking its true potential in a research context.

The Indirect, But Powerful, Path to Strength

So, if it doesn't directly build muscle, how can it possibly make you stronger? The answer lies in the indirect pathways. True strength is built on a foundation of healthy, resilient connective tissues and efficient recovery cycles. If your foundation is cracked, you can't build a skyscraper. It's that simple.

An athlete, or anyone pushing their physical limits, is in a constant cycle of breakdown and repair. You lift heavy, you create micro-tears in the muscle, you stress your tendons and ligaments, and then, hopefully, your body repairs itself to be slightly stronger than before. This process is called adaptation. But what happens when the breakdown outpaces the repair? You get injuries. You get stagnation. You get chronic pain. You hit a plateau you just can't seem to break.

BPC 157 appears to work by fundamentally tipping the scales in favor of repair. It doesn't just patch things up; our research observations suggest it helps rebuild the entire support structure, allowing for more consistent training, heavier loads over time, and a reduced risk of catastrophic injury. This is how it contributes to strength. It builds the platform upon which real strength can be constructed, safely and sustainably.

Supercharging Tendon and Ligament Health

Here’s where BPC 157’s reputation was forged. Let’s talk about connective tissue. Tendons (which connect muscle to bone) and ligaments (which connect bone to bone) are notoriously difficult to heal. Why? They have a very poor blood supply compared to muscle tissue. Less blood flow means fewer nutrients, fewer growth factors, and a much slower healing cascade. A torn tendon can be a career-ending injury for an athlete.

This is where BPC 157 has shown some of its most dramatic effects in preclinical studies. It’s been observed to significantly accelerate the healing of these tissues. One of the primary proposed mechanisms is its interaction with the growth hormone receptor and its profound impact on fibroblast proliferation. Fibroblasts are the cells responsible for creating collagen, the main structural protein in connective tissue. More active, healthy fibroblasts mean faster and more robust collagen formation.

Our team has reviewed countless studies pointing to this effect. For example, research on Achilles tendon healing in rat models showed that BPC 157 administration led to a more organized, functional collagen fiber structure in the repaired tendon. It wasn't just healed; it was healed better. What does this mean for strength? It means the 'cables' that anchor your muscles to your bones become stronger and more resilient. You can pull harder without fear of a snap. That nagging elbow tendonitis or shoulder impingement that prevents you from pressing heavy? BPC 157 is studied precisely for its potential to address those root-cause issues, clearing the way for you to train hard again.

This is not a temporary fix. This is foundational repair.

Slashing Recovery Time and Muscle Soreness

Now, let's talk about muscle itself. While BPC 157 isn’t directly anabolic, it has a profound effect on muscle recovery. After a grueling workout, your muscles are inflamed and damaged. This is normal. The subsequent inflammation (DOMS – Delayed Onset Muscle Soreness) is a sign that your body is getting to work on repairs. However, excessive or prolonged inflammation can hinder recovery and keep you out of the gym.

BPC 157 has demonstrated potent anti-inflammatory properties. But it’s not like taking an NSAID, which can sometimes blunt the signals needed for muscle growth. Instead, it seems to modulate the inflammatory response, bringing it under control more quickly without shutting down the entire regenerative process. It helps clean up the damage efficiently.

We’ve seen this anecdotally and in research focusing on muscle crush injuries. Studies have indicated that BPC 157 can speed up the healing of torn and damaged muscle tissue significantly. For someone training for strength, this translates to tangible benefits:

More Frequent Training: If you recover faster, you can hit the same muscle group again sooner, leading to a greater volume of work over time. Volume is a key driver of strength.

Higher Quality Sessions: You're not walking into the gym feeling beat up from your last session. You’re fresher, less sore, and more capable of performing at your peak and pushing for new personal records.

Injury Prevention: By healing the micro-trauma more effectively after each session, you prevent it from accumulating and turning into a full-blown strain or tear.

It’s a virtuous cycle. Faster recovery allows for better training, which leads to greater strength gains. It's an indirect effect, but a monumentally important one.

The Angiogenesis Factor: Building New Blood Pathways

This might be one of the most underrated mechanisms of BPC 157. Angiogenesis. It’s the physiological process through which new blood vessels form from pre-existing vessels. And it is absolutely critical for healing and performance.

As we mentioned, poor blood supply is the Achilles' heel (pun intended) of connective tissue repair. BPC 157 has been shown in numerous studies to upregulate Vascular Endothelial Growth Factor (VEGF), a key signaling protein that stimulates the formation of new blood vessels. More blood vessels mean more oxygen, more nutrients, and more growth factors can be delivered directly to the site of an injury. It’s like upgrading a tiny country road into a multi-lane superhighway for your body's repair crews.

This isn't just for acute injuries. For a strength athlete, enhancing blood flow to working muscles and supporting tissues can improve endurance, work capacity, and, you guessed it, recovery. The ability to efficiently clear out metabolic waste products (like lactic acid) and shuttle in nutrients is a cornerstone of performance. By potentially improving the vascular network, BPC 157 helps optimize the entire system for high-output activity. This is a profound systemic benefit that goes far beyond just patching up a single injury.

BPC 157 vs. Other Compounds: A Clear Distinction

To really understand where BPC 157 fits, it helps to compare it to other categories of compounds often associated with strength. Our team put together this table to clarify the fundamental differences in their mechanisms and goals.

Primary Mechanism

Systemic healing, angiogenesis, tissue regeneration

Direct binding to androgen receptors

Stimulation of pituitary to release Growth Hormone

Direct Effect on Strength

Indirect (via recovery and tissue integrity)

Direct (via increased muscle protein synthesis)

Indirect (via GH/IGF-1 axis, supports recovery)

Main Application

Injury repair, recovery, gut health

Muscle mass (hypertrophy), raw strength

Recovery, body composition, anti-aging

Focus Area

Connective tissues, muscle, gut, nervous system

Skeletal muscle

Systemic cellular repair and growth

Side Effect Profile

Generally considered to have a high safety profile in studies

Significant potential for hormonal disruption, etc.

Potential for water retention, insulin sensitivity issues

Role in Training

Foundational support, enables consistency and longevity

Performance enhancement, forces adaptation

Optimization, enhances the results of training/diet

As you can see, they operate in completely different worlds. Using BPC 157 is like hiring a world-class construction crew to constantly maintain and upgrade the foundation of your house. Using anabolics is like adding another floor to the building, regardless of the foundation's condition. Both might make the house 'bigger' in the short term, but only one approach is sustainable. Many researchers actually investigate combinations, such as the popular Wolverine Peptide Stack, which pairs BPC 157 with another potent regenerative peptide, TB 500, to target healing from multiple angles.

The Critical Role of Purity in Research Outcomes

Now, this is where our expertise at Real Peptides becomes paramount. The theoretical benefits of a peptide are meaningless if the product being studied is impure, improperly synthesized, or degraded. The world of peptide supply is, frankly, a bit of a wild west. It’s becoming increasingly challenging to find reliable sources.

We've found that peptides are incredibly sensitive molecules. The exact amino-acid sequencing is everything. A single mistake in the chain can render the peptide inert or, worse, create an entirely different, potentially harmful compound. This is why we are unflinching in our commitment to small-batch synthesis and rigorous third-party testing. It’s not a marketing slogan; it’s a non-negotiable scientific necessity.

When a researcher uses an underdosed or impure BPC 157 product, they won't see the expected results. They might conclude that 'BPC 157 doesn't work,' when in reality, they weren't even studying actual BPC 157. This muddies the waters for everyone and slows down the progress of legitimate research. Our guarantee of purity and consistency—whether it's our injectable BPC 157 Peptide or our orally stable BPC 157 Capsules—is designed to provide researchers with a reliable, verifiable baseline. You know exactly what you’re working with, every single time. That’s the only way to produce meaningful, reproducible data.

So, to circle back to the original question: Does BPC 157 make you stronger?

The most accurate answer is this: BPC 157 builds a stronger, more resilient biological framework that allows you to get stronger, faster and more safely than you otherwise could. It optimizes the recovery and repair processes that are the true engines of strength adaptation. It won't add 50 pounds to your bench press in a week. But it might be the very thing that heals the nagging shoulder injury that’s been holding your bench press back for the last five years. And in the long run, which one leads to greater strength? The answer is obvious.

It’s a foundational tool, not a superficial fix. For any researcher serious about understanding the long-term mechanics of human performance and resilience, it represents a fascinating and incredibly promising area of study. If you're ready to explore this potential in your own research, we encourage you to Get Started Today by exploring our full range of meticulously crafted peptides.

FAQs About BPC 157 and Strength

Frequently Asked Questions

No, absolutely not. BPC 157 is a peptide derived from a stomach protein and works through regenerative pathways. It does not interact with androgen receptors and has a completely different mechanism of action than steroids or SARMs.

It’s unlikely to have a direct, immediate impact on your one-rep max. Its contribution to strength is indirect, by improving recovery, healing injuries that limit performance, and strengthening connective tissues over time, allowing for more consistent and heavier training.

This varies greatly depending on the individual and the severity of the injury. Some preclinical studies and anecdotal reports suggest noticeable improvements in pain and mobility within one to two weeks, while deeper tissue repair can take several weeks or longer.

This is one of the most promising areas of BPC 157 research. By promoting angiogenesis (new blood vessel formation) and reducing chronic inflammation, it may help restart the healing process in old, nagging injuries that have poor blood flow and have stagnated.

Oral BPC 157, like our [BPC 157 Capsules](https://www.realpeptides.co/products/bpc-157-capsules/), is known for its excellent stability and systemic effects, particularly for gut health. For targeted musculoskeletal injuries, injectable administration is often preferred in research for more localized action, but systemic benefits can be achieved with both forms.

BPC 157 is highly effective on its own for many applications. However, researchers often study it in combination with TB 500 (as seen in our [Wolverine Peptide Stack](https://www.realpeptides.co/products/wolverine-peptide-stack/)) because they have complementary healing mechanisms, potentially creating a synergistic effect for comprehensive tissue repair.

BPC 157 is not an anabolic steroid or a controlled substance, so it would not be detected on a standard workplace drug test. However, some advanced anti-doping agencies (like WADA) have banned it for competitive athletes, so it’s critical for them to be aware of their sport’s specific regulations.

Its role in hypertrophy is secondary. By speeding up muscle repair and reducing downtime between workouts, it allows for greater training volume, which is a key driver of muscle growth. It does not, however, directly stimulate muscle protein synthesis like an anabolic agent.

In research settings, BPC 157 has demonstrated a very high safety profile with minimal reported side effects. The most common observation is temporary irritation at an injection site, which is not relevant to its systemic function.

Purity is everything. An impure or improperly synthesized peptide can be ineffective or even harmful. For reliable and reproducible research outcomes, it is essential to use a product with guaranteed purity, like those we produce at Real Peptides.

Yes, one of its widely reported effects is a reduction in Delayed Onset Muscle Soreness (DOMS). By modulating the inflammatory response and accelerating micro-tear repair, it can help you feel less sore and ready to train again sooner.

Collagen supplements provide the raw building blocks for connective tissue. BPC 157, on the other hand, is believed to act as a signaling molecule that orchestrates the repair process itself, activating fibroblasts and promoting blood flow. They work on very different levels of the healing cascade.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

BPC-157 Studied Sports Injury: Dosing Protocols and Administration Routes

BPC-157 studied sports injury research reveals significant dosing inconsistency across published trials. Most rodent studies used subcutaneous or intraperitoneal injection at 10 micrograms per kilogram body weight daily. Translating to approximately 700–800 micrograms for a 70-kilogram human using direct dose conversion. However, human trials (the limited number that exist) typically employ 200–500 microgram doses administered subcutaneously near the injury site. Administration route matters substantially. A 2017 comparative study found that local subcutaneous injection near the injury site produced 2.1× faster healing compared to systemic intraperitoneal administration in rat models. The mechanism likely involves direct diffusion into injured tissue, bypassing systemic circulation and first-pass metabolism. Intramuscular injection protocols appear in some research, but subcutaneous administration remains the most studied route for musculoskeletal injuries. Timing protocols vary significantly. Some studies administer BPC-157 immediately post-injury and continue for 7–14 days. Others begin administration 24–48 hours after injury to allow initial inflammatory signaling to proceed uninterrupted. Research from the University of Zagreb (the institution responsible for most BPC-157 foundational work) suggests that administration during the proliferative phase (days 3–10 post-injury) produces optimal structural outcomes, as this window corresponds to peak fibroblast activity and co…
STORAGE

Storage and Reconstitution Requirements for Joint Research Protocols

BPC-157 is supplied as lyophilized powder and must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, the solution remains stable at 2–8°C (standard refrigeration) for up to 28 days, though some research groups use it within 14 days to minimize degradation. Temperature excursions above 8°C denature the peptide irreversibly. A single overnight incident at room temperature renders the vial unusable, even if it appears visually unchanged. Unlike larger proteins, BPC-157's 15-amino-acid chain is vulnerable to oxidation; antioxidant-free bacteriostatic water (0.9% benzyl alcohol in sterile water) is the standard reconstitution vehicle. Cartalax stability depends on formulation. Oral capsules can be stored at room temperature (15–25°C) in a sealed container away from moisture. Injectable Cartalax follows the same lyophilized storage rules as BPC-157: −20°C before reconstitution, 2–8°C after mixing, use within 28 days. Because Cartalax is a tetrapeptide (even shorter than BPC-157), it's more susceptible to hydrolysis. Some researchers prepare single-use vials rather than multi-dose vials to avoid repeated punctures that introduce air and potential contaminants. Reconstitution errors are the most common failure point in peptide research. Inject bacteriostatic water slowly down the side of the vial. Never directly onto the powder. To prevent foaming and peptide aggregation. Swirl gently; do not shake. Let the vial sit for 60–90 seconds to fully dissolve b…
02

Question drills

Open a question for its connected answer.

01What If I'm Researching BPC-157 for a Lab Study on IBD Mechanisms?+

Use peptide batches with full amino acid sequencing documentation and sterility testing from FDA-registered 503B facilities or ISO-certified international suppliers. Variability in synthesis quality between suppliers is significant. We've seen batches labeled as BPC-157 that contained less than 85% target peptide with unidentified degradation products. For in vivo studies, verify endotoxin levels below 0.5 EU/mg to prevent confounding inflammatory responses. Dosing in published rodent studies ranged from 10 micrograms to 1 milligram per kilogram body weight daily. Titrate based on your specific model and endpoint.

SOURCE / realpeptides.co ↗
02What If VEGFR2 Is Already Saturated by Endogenous VEGF-A?+

Administer BPC-157 alongside VEGF-A. The two ligands don't compete for the same binding site based on receptor kinetics observed in endothelial culture studies. If VEGF-A levels are elevated but ineffective (common in chronic wounds), BPC-157 may stabilize VEGFR2 in the active conformation longer than transient VEGF-A pulses, extending downstream signaling duration. Structural evidence suggests BPC-157 binds an allosteric site, which would explain synergistic effects when both ligands are present. Co-administration in rat gastric ulcer models produced 81% ulcer area reduction versus 63% with BPC-157 alone.

SOURCE / realpeptides.co ↗
03What If I'm Unsure How Long the Vial Was Left Out?+

Default to the worst-case exposure scenario. For lyophilized powder, assume 48 hours at room temperature (acceptable risk). For reconstituted peptides, assume 12+ hours (discard threshold). Peptide stability isn't binary, but research integrity requires conservative assumptions when exposure duration is unknown. The cost of a replacement vial is lower than the cost of invalid research data.

SOURCE / realpeptides.co ↗
04What If You Administer Both Peptides at the Same Time Every Day?+

Concurrent administration is effective, but you lose the sequencing advantage. Administering BPC-157 20–30 minutes before Cartalax allows vascular changes to begin before chondrocyte activity peaks, maximizing nutrient availability when matrix synthesis is most active. If both are given simultaneously, the processes overlap rather than reinforce. Not harmful, but measurably less efficient in head-to-head comparisons. Research from the Zagreb group showed 18% lower hydroxyproline deposition in concurrent-dose groups versus staggered groups at day 21.

SOURCE / realpeptides.co ↗
05What If I've Tried L-Glutamine and Probiotics Without Improvement?+

L-glutamine supports enterocyte metabolism but doesn't directly upregulate tight junction genes. Probiotics modulate microbial balance but take 6–12 weeks to show structural effects. If you've addressed inflammation and microbiome imbalance without measurable permeability improvement, the issue is likely at the tight junction protein level itself. The bpc-157 intestinal permeability mechanism targets that directly: it increases occludin and ZO-1 transcription regardless of microbial composition or substrate availability. Consider a 4–6 week trial at research-grade doses (200–500 μg daily subcutaneously for a 70kg individual, extrapolated from rodent mg/kg dosing) while maintaining glutamine and probiotic use. The peptide addresses a different mechanistic layer.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Published Studies

Review Articles Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healinghttps://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ Gastric Pentadecapeptide Body Protection Compound BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healinghttps://pubmed.ncbi.nlm.nih.gov/30915550/ Stable Gastric Pentadecapeptide BPC 157 and Wound Healinghttps://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/ Multifunctionality and Possible Medical Application of the Peptide BPC 157https://pubmed.ncbi.nlm.nih.gov/40005999/ Emerging Use of BPC-157 in Orthopaedic Sports Medicinehttps://pubmed.ncbi.nlm.nih.gov/40756949/ Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon and In Vitro Stimulates Tendocytes Growthhttps://pubmed.ncbi.nlm.nih.gov/14554208/ Pentadecapeptide BPC 157 Improves Ligament Healing in the Rathttps://pubmed.ncbi.nlm.nih.gov/20225319/ The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Fibroblast Outgrowth, Cell Survival, and Cell Migrationhttps://journals.physiology.org/doi/abs/10.1152/japplphysiol.00945.2010 Stable Gastric Pentadecapeptide BPC 157 and Wound Healinghttps://pubmed.ncbi.nlm.nih.gov/34267654/ Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Healing With BPC 157https://pmc.ncbi.nlm.nih.gov/articles/PMC12944561/ The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice. This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information. BPC-157 is not FDA-approved for any medical indication in the United States. Its use remains investigational, and any clinical use may be considered off-label or non-approved depending on context. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment. R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law. # KPV

RESEARCH

Tissue-Specific Gene Expression Patterns in BPC-157 Research

BPC-157 gene expression isn't uniform across tissue types. The peptide's genetic effects adapt to the injury context. In gastric ulcer models, BPC-157 upregulates mucin genes (MUC2, MUC5AC) and tight junction proteins (occludin, claudin-1), which restore the protective mucosal barrier. A 2014 study in the World Journal of Gastroenterology documented 2.8-fold increases in occludin mRNA expression in BPC-157-treated gastric tissue compared to controls, correlating with faster ulcer closure rates (complete healing in 7–10 days vs 14–18 days in untreated groups). In tendon and ligament injury models, the genetic response shifts toward collagen remodeling and mechanical strength restoration. Research from the Journal of Applied Physiology showed BPC-157 increased tenomodulin gene expression. A marker of mature, load-bearing tendon tissue. By 220% at 14 days post-injury. This isn't just accelerated healing; it's qualitatively improved tissue architecture. Tenomodulin-positive tendons exhibit higher tensile strength and better alignment of collagen fibers under mechanical load, reducing re-injury risk. Bone healing research reveals another distinct genetic profile. BPC-157 administration increased osteocalcin (a marker of bone formation) mRNA levels by 3.1-fold in fracture healing models, alongside elevated Runx2 gene expression. The master transcription factor for osteoblast differentiation. The peptide appears to accelerate the transition from cartilaginous callus to mineralized bone, shortening the consolidation phase of fracture repair by 30–40% in rodent studies. Vascular injury models show the most dramatic VEGF upregulation. In ligated artery models (where blood flow is surgically blocked), BPC-157 treatment increased VEGF gene expression by 400–500% in ischemic tissue distal to the blockage, driving rapid collateral vessel formation. This level of transcriptional upregulation approaches what's seen with direct VEGF gene therapy, but without requiring genetic modification or viral vectors. The pattern suggests BPC-157 acts as a context-dependent genetic modulator. Amplifying whichever repair pathways are most relevant to the specific tissue injury present. This adaptability is rare among regenerative compounds and explains why the peptide demonstrates efficacy across such diverse injury models. For researchers selecting Real Peptides for BPC-157 studies, understanding these tissue-specific gene expression profiles is critical for designing protocols that measure the right genetic markers at the right timepoints.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Studied Ulcerative Colitis Research: Model Comparison

TNBS Colitis Intrarectal ethanol + TNBS Transmural, mixed Th1/Th17 7–14 days 10 mcg/kg IP daily Moderate. More Crohn's-like but validates mucosal healing Acetic Acid Colitis Intra…